RE:RE:RE:RE: McWhirter's holdings BNN MARKET CALL
THis was back then. 2014.
Three top stock picks from Selective Asset’s Robert McWhirter
Special to The Globe and Mail
Published
Last updated
ProMetic Life Sciences (PLI TSX)
ProMetic’s stock hit a 52-week high today. ProMetic is a manufacturing company with the bonus of PBI-4050, an interesting drug discovery. ProMetic has proprietary filtering technology used for large scale purification of drugs and is using this technology to extract proteins from plasma at their plant in Laval, Quebec. Clinical studies of three proteins extracted from plasma: plasminogen, IVIG and AAT are expected over the next nine months. Roche spent $8.3-billion cash to acquire InterMune, a U.S. company with one approved drug, Pirfenidone used to treat idiopathic pulmonary fibrosis (IPF). Doug Cooper of Beacon Securities recently noted that ProMetic’s PBI-4050 also targets IPF and has also shown promising results in kidney, heart and liver fibrosis. Doug notes, “In head-to-head studies published last fall, PBI-4050 showed better efficacy (worked better) than Pirfenidone.” Alan Ridgeway of Paradigm Capital’s target is $2.90. Doug Cooper’s target is $3.50. ProMetic is our eighth largest personal holding. I expect to be buying more in the coming days.